Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
Completed · Phase 1
Conditions studied: Chronic Myelogenous Leukemia
In brief
The purpose of this study if to investigate the effect of lonafarnib (SCH66336) in combination with Gleevec in the treatment of CML.
Key facts
- Study ID
- NCT00047502
- Run by
- M.D. Anderson Cancer Center
- People needed
- 23
- Starts
- 2002-11-01
- Expected to finish
- 2006-04-10
- Last updated by the study team
- 2018-11-07
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- M.D. Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.